188,035 Shares in HilleVax, Inc. (NASDAQ:HLVX) Acquired by Verition Fund Management LLC

Verition Fund Management LLC bought a new position in HilleVax, Inc. (NASDAQ:HLVX) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 188,035 shares of the company’s stock, valued at approximately $331,000. Verition Fund Management LLC owned 0.38% of HilleVax at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in HLVX. Frazier Life Sciences Management L.P. lifted its stake in HilleVax by 8.5% in the second quarter. Frazier Life Sciences Management L.P. now owns 10,617,062 shares of the company’s stock worth $153,523,000 after acquiring an additional 835,590 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of HilleVax in the 2nd quarter valued at about $6,960,000. Trium Capital LLP purchased a new stake in shares of HilleVax in the 3rd quarter worth approximately $798,000. Ensign Peak Advisors Inc boosted its stake in shares of HilleVax by 164.8% during the second quarter. Ensign Peak Advisors Inc now owns 311,784 shares of the company’s stock valued at $4,508,000 after purchasing an additional 194,038 shares in the last quarter. Finally, Affinity Asset Advisors LLC purchased a new position in HilleVax during the second quarter valued at approximately $3,844,000. Institutional investors own 86.42% of the company’s stock.

HilleVax Stock Down 1.0 %

Shares of NASDAQ:HLVX opened at $1.96 on Friday. The company has a market capitalization of $97.63 million, a price-to-earnings ratio of -0.63 and a beta of 0.81. The firm has a 50 day moving average of $1.88 and a 200 day moving average of $4.20. HilleVax, Inc. has a 52 week low of $1.55 and a 52 week high of $20.22.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). On average, sell-side analysts expect that HilleVax, Inc. will post -2.64 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.